Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165317 · ClinicalTrials.gov registry record · Phase 3
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
A Phase 3 study of Non-muscle Invasive Bladder Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 1,068
- Enrollment target
- 20
- Study locations
NCT04165317 is a Phase 3 study of Non-muscle Invasive Bladder Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1,068 participants, above the 195-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (448% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT04165317, a Phase 3 study of Non-muscle Invasive Bladder Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,068 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B). In Part A (enrollment closed), each participant was assigned to one of three study treatment groups. * One group is given sasanlimab and BCG at the study clinic. * The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only. * The third group is given BCG only and will not receive sasanlimab. In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor. \- Both groups will be given sasanlimab at the study clinic. On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B. The decision to discontinue enrollment to Part B was not made for safety reasons.
Conditions Studied
Interventions
- DRUG PF-06801591
- DRUG Bacillus Calmette-Guerin
Study Locations (20)
California
- Koman Family Outpatient Pavilion - La Jolla
- Sulpizio Cardiovascular Center at UC San Diego Health - La Jolla
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) - La Jolla
- UC San Diego Moores Cancer Center - La Jolla
- University of California Irvine Medical Center - Orange
- UC San Diego Medical Center - Hillcrest - San Diego
Illinois
- John H. Stroger, Jr. Hospital of Cook County - Chicago
- DuPage Medical Group - Lisle
- DuPage Medical Group Ambulatory Surgery Center - Lombard
- DuPage Medical Group - Lombard
- Edward Hospital - Naperville
Florida
- Urological Research Network Corp - Hialeah
- UF Health Jacksonville - Jacksonville
- UF Health North - Jacksonville
Arizona
- Arizona Urology Specialists - Tucson
Arkansas
- Arkansas Urology - Little Rock
Colorado
- The Urology Center of Colorado - Denver
Louisiana
- Ochsner LSU Health Shreveport - Regional Urology - Shreveport
Maryland
- Chesapeake Urology Research Associates - Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,068 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2026-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165317
The ClinicalTrials.gov registry entry for NCT04165317 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,068 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 195-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (448% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which PF-06801591 is the first listed.
NCT04165317 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT04165317 about?
NCT04165317 is a clinical study titled "A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer". The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surg...
What is the current status of trial NCT04165317?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,068 participants. The study started on 2019-12-30. Estimated completion is 2026-12-02.
What conditions does trial NCT04165317 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT04165317?
The interventions under investigation include: PF-06801591 (DRUG), Bacillus Calmette-Guerin (DRUG).
Who is sponsoring clinical trial NCT04165317?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04165317 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
RECRUITING · Phase 3
-
Intravesical BCG vs GEMDOCE in NMIBC
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
ACTIVE NOT RECRUITING · Phase 3
-
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
ACTIVE NOT RECRUITING · Phase 3
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.